Patents by Inventor Greg M. Delgoffe

Greg M. Delgoffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240335473
    Abstract: The present disclosure provides methods for expanding tumor-infiltrating lymphocytes (TILs), such as tumor-infiltrating T cells, utilizing an agonist of PGC1? in vivo, ex vivo, or both. Exhausted T cells present in the TIL population fail to effectively proliferate, produce cytokines, or kill target cells. The present disclosure provides methods to correct these defects through the use of pharmacologic agents to reprogram the metabolism of the exhausted intratumoral T cells. Exemplary agonists of PGC1? include proliferator-activated receptor (PPAR)-gamma agonists (e.g., a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar), AMPK activators (e.g., 5-aminoimidazole-4-carboxamide ribonucleotide, AICAR), and sirtuin activators (e.g., resveratrol, SRT1720, SRT2104, SRT2183, SRT1460). Also provided are kits can compositions that can be used with such methods.
    Type: Application
    Filed: June 17, 2024
    Publication date: October 10, 2024
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventor: Greg M. Delgoffe
  • Publication number: 20240325537
    Abstract: The present disclosure provides compositions, including modified peripheral blood mononuclear cells (PBMCs) with reduced expression of Slc16a11 and/or reduced activity of MCT11. Also provided are siRNAs and gRNAs targeting Slc16a11. Methods of using the disclosed compositions in the treatment of cancer are also provided.
    Type: Application
    Filed: July 19, 2022
    Publication date: October 3, 2024
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Greg M. Delgoffe, Ronal Peralta
  • Patent number: 12048717
    Abstract: The present disclosure provides methods for expanding tumor-infiltrating lymphocytes (TILs), such as tumor-infiltrating T cells, utilizing an agonist of PGC1? in vivo, ex vivo, or both. Exhausted T cells present in the TIL population fail to effectively proliferate, produce cytokines, or kill target cells. The present disclosure provides methods to correct these defects through the use of pharmacologic agents to reprogram the metabolism of the exhausted intratumoral T cells. Exemplary agonists of PGC1? include proliferator-activated receptor (PPAR)-gamma agonists (e.g., a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar), AMPK activators (e.g., 5-aminoimidazole-4-carboxamide ribonucleotide, AICAR), and sirtuin activators (e.g., resveratrol, SRT1720, SRT2104, SRT2183, SRT1460). Also provided are kits can compositions that can be used with such methods.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: July 30, 2024
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventor: Greg M. Delgoffe
  • Publication number: 20240011046
    Abstract: Oncolytic viruses encoding a recombinant form of TGF-? engineered to prevent homodimerization and recruitment of TGF-? receptor I are described. The engineered TGF-? monomers function as dominant-negative TGF-? inhibitors. Oncolytic viruses encoding a TGF-? monomer can be used for cancer immunotherapy to inhibit the immunosuppressive tumor microenvironment.
    Type: Application
    Filed: August 27, 2021
    Publication date: January 11, 2024
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Greg M. Delgoffe, Andrew P. Hinck, Kristin DePeaux
  • Publication number: 20230381312
    Abstract: Provided are improved methods for making immune effector cells, as well as improved immune effector cells generated using the methods. The improved T cells have improved respiratory capacity and mitochondrial mass. Adoptive T cell immunotherapies using such cells demonstrate improved survival, expansion, and persistence in vivo.
    Type: Application
    Filed: October 27, 2021
    Publication date: November 30, 2023
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Greg M. Delgoffe, Andrew Tyler Frisch
  • Patent number: 11786569
    Abstract: Recombinant oncolytic viruses (OVs) that express one or more metabolic modulator proteins, such as an adipokine (e.g., leptin or chemerin), insulin, and/or IGF-1, and methods of their use to treat cancer, for example in immunotherapy anti-cancer treatments. In some examples, such recombinant OVs and methods increase T cell infiltration into the tumor or tumor microenvironment.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: October 17, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Greg M. Delgoffe, Dayana Rivadeneira, Padmavathi Sampath, Stephen H. Thorne
  • Patent number: 11583555
    Abstract: The present disclosure provides recombinant T cells that include a vector encoding one or more of peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1-alpha (PGC1?), mitochondrial transcription factor A (Tfam), GA binding protein transcription factor alpha subunit (GABPA), and estrogen-related receptor alpha (ERR?). Such recombinant T cells can also include a chimeric antigen receptor (CAR) or a recombinant T cell receptor (TCR). Methods of using these recombinant T cells in cancer immunotherapy are provided. Also provided are kits and compositions that can be used with such methods.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: February 21, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventor: Greg M. Delgoffe
  • Publication number: 20200330534
    Abstract: Recombinant oncolytic viruses (OVs) that express one or more metabolic modulator proteins, such as an adipokine (e.g., leptin or chemerin), insulin, and/or IGF-1, and methods of their use to treat cancer, for example in immunotherapy anti-cancer treatments. In some examples, such recombinant OVs and methods increase T cell infiltration into the tumor or tumor microenvironment.
    Type: Application
    Filed: January 28, 2019
    Publication date: October 22, 2020
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Greg M. Delgoffe, Dayana Rivadeneira, Padmavathi Sampath, Stephen H. Thorne
  • Publication number: 20200010552
    Abstract: The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis.
    Type: Application
    Filed: June 12, 2019
    Publication date: January 9, 2020
    Inventors: Dario A. A. Vignali, Seng-Ryong Woo, Greg M. Delgoffe
  • Publication number: 20190350973
    Abstract: The present disclosure provides recombinant T cells that include a vector encoding one or more of peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1-alpha (PGC1?), mitochondrial transcription factor A (Tfam), GA binding protein transcription factor alpha subunit (GABPA), and estrogen-related receptor alpha (ERR? ). Such recombinant T cells can also include a chimeric antigen receptor (CAR) or a recombinant T cell receptor (TCR). Methods of using these recombinant T cells in cancer immunotherapy are provided. Also provided are kits and compositions that can be used with such methods.
    Type: Application
    Filed: June 26, 2017
    Publication date: November 21, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventor: Greg M. Delgoffe
  • Publication number: 20190307796
    Abstract: The present disclosure provides methods for expanding tumor-infiltrating lymphocytes (TILs), such as tumor-infiltrating T cells, utilizing an agonist of PGC1? in vivo, ex vivo, or both. Exhausted T cells present in the TIL population fail to effectively proliferate, produce cytokines, or kill target cells. The present disclosure provides methods to correct these defects through the use of pharmacologic agents to reprogram the metabolism of the exhausted intratumoral T cells. Exemplary agonists of PGC1? include proliferator-activated receptor (PPAR)-gamma agonists (e.g., a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar), AMPK activators (e.g., 5-aminoimidazole-4-carboxamide ribonucleotide, AICAR), and sirtuin activators (e.g., resveratrol, SRT1720, SRT2104, SRT2183, SRT1460). Also provided are kits can compositions that can be used with such methods.
    Type: Application
    Filed: June 5, 2017
    Publication date: October 10, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventor: Greg M. Delgoffe
  • Publication number: 20170137524
    Abstract: The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis.
    Type: Application
    Filed: November 28, 2016
    Publication date: May 18, 2017
    Inventors: Dario A. A. Vignali, Seng-ryong Woo, Greg M. Delgoffe
  • Patent number: 9540439
    Abstract: The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis. The present invention satisfies this and other needs by demonstrating that the regulatory T cell (Treg)-restricted neuropilin-1 (Nrp 1) interacts with the cell surface ligand semaphorin-4a (Sema4a) (e.g., on conventional T cells (Tconv), conventional dendritic cells (cDCs), and/or plasmacytoid dendritic cells (pDCs)) to potentiate reg function and enhance their survival at inflammatory sites.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: January 10, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: Dario A. A. Vignali, Seng-ryong Woo, Greg M. Delgoffe
  • Publication number: 20150266959
    Abstract: The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis. The present invention satisfies this and other needs by demonstrating that the regulatory T cell (Treg)-restricted neuropilin-1 (Nrp 1) interacts with the cell surface ligand semaphorin-4a (Sema4a) (e.g., on conventional T cells (Tconv), conventional dendritic cells (cDCs), and/or plasmacytoid dendritic cells (pDCs)) to potentiate reg function and enhance their survival at inflammatory sites.
    Type: Application
    Filed: October 8, 2013
    Publication date: September 24, 2015
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Dario A. A. Vignali, Seng-ryong Woo, Greg M. Delgoffe